Search results for "AGENT"

showing 10 items of 8904 documents

Cognitive effects of labeled addictolytic medications

2017

Abstract Introduction Alcohol, tobacco, and illegal drug usage is pervasive throughout the world, and abuse of these substances is a major contributor to the global disease burden. Many pharmacotherapies have been developed over the last 50 years to target addictive disorders. While the efficacy of these pharmacotherapies is largely recognized, their cognitive impact is less known. However, all substance abuse disorders are known to promote cognitive disorders like executive dysfunction and memory impairment. These impairments are critical for the maintenance of addictive behaviors and impede cognitive behavioral therapies that are regularly administered in association with pharmacotherapie…

medicine.medical_specialtySubstance-Related Disordersmedia_common.quotation_subjectAlcohol abuse03 medical and health scienceschemistry.chemical_compoundCognition0302 clinical medicinemedicineAnimalsHumansVareniclinePsychiatryBiological PsychiatryNalmefenemedia_commonPharmacologyAddictionCognitionmedicine.disease030227 psychiatrySubstance abusechemistryPsychology030217 neurology & neurosurgeryCentral Nervous System AgentsClinical psychologymedicine.drugExecutive dysfunctionBuprenorphineProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct

Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature …

2010

Summary Background There is clear evidence from two systematic reviews that radiotherapy (RT) reduces the risk of local recurrence in patients with resectable rectal cancer, though the data on survival are still equivocal. Objective To assess the effects of chemotherapy combined concomitantly with radiotherapy (CRT) on the increase of overall survival, and on the prevention of local recurrence and distant metastases. Data sources Computerized bibliographic searches of MEDLINE and CANCERLIT (1970–2008) were supplemented with hand searches of reference lists. Study selection Studies were included if they were randomized controlled trials (RCTs) comparing preoperative or postoperative CRT to p…

medicine.medical_specialtySurvivalColorectal cancermedicine.medical_treatmentPopulationAntineoplastic Agentslaw.inventionRectal carcinomaRandomized controlled triallawRisk of mortalityHumansMedicineMeta-analysiRadiology Nuclear Medicine and imagingNeoplasm Metastasiseducationeducation.field_of_studyRadiotherapyRectal Neoplasmsbusiness.industryChemoradiotherapyGeneral Medicinemedicine.diseaseCombined Modality TherapySurgeryRadiation therapyOncologyConcomitantMeta-analysisbusinessPublication BiasChemoradiotherapyCancer Treatment Reviews
researchProduct

Is global elimination of HCV realistic?

2017

The elimination of hepatitis C virus (HCV) has been made possible through the availability of new antiviral drugs which may now be administered to all patients with HCV infection, even those with decompensated cirrhosis. The goal of the World Health Organization (WHO) is to reduce the incidence of chronic hepatitis infection from the current 6-10 million to 0.9 million cases of chronic infections by 2030, and annual deaths from 1.4 million to fewer than 0.5 million. Achieving these targets will require full implementation of epidemiological knowledge of HCV infection, screening and testing practices and strategies to link HCV patients to care. This review will focus on the current state of …

medicine.medical_specialtySustained Virologic ResponseHepatitis C virusCost-Benefit Analysismedicine.disease_causeGlobal HealthWorld Health OrganizationAntiviral AgentsWorld health03 medical and health sciences0302 clinical medicineChronic hepatitisInternal medicineEpidemiologymedicineHumansMass Screening030212 general & internal medicineDisease EradicationIntensive care medicineSubstance Abuse Intravenouslinkage to caredirect antiviral agentHepatologybusiness.industryscreeningIncidence (epidemiology)Hcv clearancevirus diseasesHepatologyPatient Acceptance of Health CareHepatitis Cdigestive system diseases030211 gastroenterology & hepatologybusinessPatient awarenessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Modulation of central corneal thickness by various riboflavin eyedrop compositions in porcine corneas

2012

Purpose To evaluate the modulatory effect of various riboflavin 0.1% and 0.2% compositions on the central corneal thickness (CCT) in fresh porcine corneas. Setting Department of Ophthalmology, Johannes Gutenberg University of Mainz, Mainz, Germany. Design Experimental study. Methods The CCT in freshly enucleated porcine globes was measured by ultrasound pachymetry before and after (if applicable) deepithelialization and every 10 minutes thereafter during 120 minutes of eyedrop application. In Groups 1 and 2 (controls), no eyedrops were applied. In Groups 3 and 4, isotonic riboflavin eyedrops were used. In Groups 5 to 9, hypotonic riboflavin eyedrops were given. In Groups 10 and 11, preparat…

medicine.medical_specialtySwineRiboflavinRiboflavinCorneaCorneal edemaCorneaOphthalmologyIsotonicAnimalsMedicineBody Weights and MeasuresUltrasonographyPhotosensitizing Agentsbusiness.industryCorneal EdemaOsmolar ConcentrationUltrasound pachymetryHydrogen-Ion ConcentrationSensory SystemsSurgeryOphthalmologyCross-Linking ReagentsOphthalmic solutionsmedicine.anatomical_structurePhotochemotherapySurgeryOphthalmic SolutionsbusinessJournal of Cataract and Refractive Surgery
researchProduct

European Society of Hypertension Working Group on Obesity: background, aims and perspectives.

2007

Clinica Medica, University ofMilano-Bicocca, Ospedale San Gerardo, Monza, Milan, ItalyCorrespondence and requests for reprints to Professor Jens Jordan, ChairmanWorking Group on Obesity, Franz Volhard Clinical Research Center, HELIOSKlinikum Berlin and Medical Faculty of the Charite´, Wiltbergstrase 50, 13125Berlin, GermanyTel: +49 30 9417 2220; fax: +49 30 9417 2265; e-mail: jens.jordan@charite.de

medicine.medical_specialtySympathetic Nervous SystemPhysiologybusiness.industryNutritional statusBlood PressureBaroreflexWeight LoSurgeryEuropeAntihypertensive AgentFamily medicineHypertensionWeight LossInternal MedicineMedicineHumansObesityCardiology and Cardiovascular MedicinebusinessAntihypertensive AgentsSocieties MedicalJournal of hypertension
researchProduct

Renal artery denervation for treating resistant hypertension: Definition of the disease, patient selection and description of the procedure

2012

Arterial hypertension is responsible for a significant burden of cardiovascular morbidity and mortality, worldwide. Although several rational and integrated pharmacological strategies are available, the control of high blood pressure still remains largely unsatisfactory. Failure to achieve effective blood pressure control in treated hypertensive patients may have a substantial impact on individual global cardiovascular risk, since it significantly increases the risk of developing hypertension-related macrovascular and microvascular complications. Arterial hypertension is arbitrarily defined as 'resistant' or 'refractory' when the recommended blood pressure goals (clinic blood pressure below…

medicine.medical_specialtySympathetic nervous systemSettore MED/09 - Medicina InternahypertensionDrug ResistanceFemoral arteryRisk AssessmentNephropathyPharmacotherapyRenal ArteryRisk Factorsmedicine.arteryInternal medicinemedicineInternal MedicineHumansArterial PressureRenal arterySympathectomyrenal artery denervationglobal cardiovascular riskantihypertensive therapyAntihypertensive AgentsSettore MED/14 - NefrologiaDenervationrefractory hypertensiontreatmentbusiness.industryPatient SelectionType 2 Diabetes Mellitusresistant hypertensionmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolaremedicine.anatomical_structureBlood pressureTreatment Outcomeresistant hypertension refractory hypertension renal artery denervation antihypertensive therapy global cardiovascular risk.resistant-hypertension; treatment; hypertensionCardiologyCatheter AblationHypertension treatment; Resistant-hypertension treatment; Antihypertensive Agents; Humans; Hypertension; Patient Selection; Renal Artery; Risk Assessment; Risk Factors; Sympathectomy; Treatment Outcome; Arterial Pressure; Catheter Ablation; Drug Resistance; Internal Medicine; Cardiology and Cardiovascular MedicinebusinessCardiology and Cardiovascular Medicineresistant-hypertension
researchProduct

Functional roles of the sweet taste receptor in oral and extraoral tissues

2014

International audience; Purpose of review: This review summarizes and discusses the current knowledge about the physiological roles of the sweet taste receptor in oral and extraoral tissues. Recent findings: The expression of a functional sweet taste receptor has been reported in numerous extragustatory tissues, including the gut, pancreas, bladder, brain and, more recently, bone and adipose tissues. In the gut, this receptor has been suggested to be involved in luminal glucose sensing, the release of some satiety hormones, the expression of glucose transporters, and the maintenance of glucose homeostasis. More recently, the sweet taste receptor was proposed to regulate adipogenesis and bon…

medicine.medical_specialtyTasteinsulinobesitysweetenerProtein ConformationUrinary BladderMedicine (miscellaneous)BiologyBioinformaticsReceptors G-Protein-Coupled03 medical and health sciences0302 clinical medicinestomatognathic systemInternal medicineInsulin Secretion[SDV.IDA]Life Sciences [q-bio]/Food engineeringmedicineAnimalsHumans[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringLymphocytesInsulin secretionReceptor030304 developmental biologyCARBOHYDRATES: Edited by Luc Tappy and Bettina Mittendorfer0303 health sciencesPolymorphism GeneticNutrition and Dieteticsdiabetesdigestive oral and skin physiologyfood and beveragesHeartSweetening agentsSweet tastetaste receptor functionTaste BudsGastrointestinal TractEndocrinologyAdipose TissuecarbohydrateSweetening AgentsTasteModels Animal030217 neurology & neurosurgeryInsulin metabolism
researchProduct

Combined sub-optimal doses of Rosuvastatin and Bexarotene impairs angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox…

2015

Aim: Mononuclear cell (MC) infiltration into the arterial subendothelium is a key event in atherogenesis. Rosuvastatin (Rosu) and bexarotene (Bex) exert anti-inflammatory activity, but serious dose-related adverse effects have emerged. The need for safer and effective strategies to prevent and treat atherosclerosis led us to test the effect of combined use of both drugs on angiotensin II (Ang-II)-induced arterial MC recruitment. Results: Vehicle, Rosu (10–30 nM), Bex (0.3–1 μM), or a combination of both were administered to human umbilical arterial endothelial cells (HUAECs) 20 h before stimulation with 1 μM Ang-II (4 h). Surprisingly, a combination of Rosu (10 nM)+Bex (0.3 μM), which did n…

medicine.medical_specialtyTetrahydronaphthalenesPhysiologyPeroxisome Proliferator-Activated ReceptorsClinical BiochemistryCCL2BiologyNitric OxideBiochemistryPeripheral blood mononuclear cellCell LineInternal medicineCell AdhesionmedicineAnticarcinogenic AgentsHumansRosuvastatinInterleukin 8Rosuvastatin CalciumMolecular BiologyGeneral Environmental ScienceSistema cardiovascularBexaroteneSulfonamidesDiabetisArtèriesAngiotensin IIMembrane ProteinsNADPH OxidasesArteriesCell BiologyAngiotensin IIFluorobenzenesCXCL1Original Research CommunicationsPyrimidinesRetinoid X ReceptorsEndocrinologyNADPH Oxidase 5BexaroteneLeukocytes MononuclearGeneral Earth and Planetary SciencesSignal transductionSignal Transductionmedicine.drug
researchProduct

Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

2020

BACKGROUND Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune thrombotic microangiopathy. Caplacizumab, an anti-von Willebrand Factor Nanobody® , is effective for treating aTTP episodes and is well tolerated. OBJECTIVES AND METHODS In the phase 3 HERCULES trial (NCT02553317), patients with aTTP received double-blind caplacizumab or placebo during daily therapeutic plasma exchange (TPE) and for ≥30 days thereafter. Patients who experienced an exacerbation while on blinded study drug treatment switched to receive open-label caplacizumab plus re-initiation of daily TPE. Exacerbations were defined as recurrence of disease occurring within 30 days after ce…

medicine.medical_specialtyThrombotic microangiopathyExacerbation610 Medicine & health030204 cardiovascular system & hematologyvon Willebrand factorPlacebocaplacizumabthrombotic thrombocytopenic03 medical and health sciences0302 clinical medicineVon Willebrand factorFibrinolytic AgentsInternal medicineMedicineHumansPlatelet610 Medicine & healthAdverse effectADAMTS13 proteinAcquired Thrombotic Thrombocytopenic PurpurabiologyPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryBrief ReportHematologySingle-Domain Antibodiesmedicine.diseaseTHROMBOSISpurpurabiology.proteinCaplacizumabbusinessJournal of thrombosis and haemostasis : JTH
researchProduct

Release of non-neuronal acetylcholine from the isolated human placenta is affected by antidepressants.

2007

Non-neuronal acetylcholine (ACh) is released from the human placenta into the extracellular space via organic cation transporters (OCTs). The present experiments investigated whether ACh release from epithelial cells is affected by drugs which are substrates of OCTs. The antidepressant drugs amitriptyline and doxepine were tested as both substances are not approved for pregnant women but frequently used. Release of ACh was measured in 10 min intervals over a period of 100 min. Test substances were added from t=50 min of incubation onwards. The effect was calculated by comparing the ACh release of the last three samples (t=70-100 min; B2) with that immediately before the application of the t…

medicine.medical_specialtyTime FactorsAmitriptylinePlacentaVasodilator AgentsPharmacologyIn Vitro TechniquesGeneral Biochemistry Genetics and Molecular BiologyTheophyllinePregnancyInternal medicinemedicineExtracellularHumansHypoglycemic AgentsAmitriptylineGeneral Pharmacology Toxicology and PharmaceuticsIncubationNeuronsOrganic cation transport proteinsbiologyDose-Response Relationship DrugChemistryHuman placentaGeneral MedicineAcetylcholineAntidepressive AgentsMetforminNon neuronal acetylcholineEndocrinologybiology.proteinMinoxidilAntidepressantFemaleDoxepinAcetylcholinemedicine.drugLife sciences
researchProduct